Literature DB >> 14724160

Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis.

M D Rutter1, B P Saunders, G Schofield, A Forbes, A B Price, I C Talbot.   

Abstract

BACKGROUND AND AIMS: Colonoscopic surveillance for cancer in longstanding extensive ulcerative colitis relies heavily on non-targeted mucosal biopsies. Chromoendoscopy can aid detection of subtle mucosal abnormalities. We hypothesised that routine pancolonic indigo carmine dye spraying would improve the macroscopic detection of dysplasia and reduce the dependence on non-targeted biopsies. PATIENTS AND METHODS: One hundred patients with longstanding extensive ulcerative colitis attending for colonoscopic surveillance underwent "back to back" colonoscopies. During the first examination, visible abnormalities were biopsied, and quadrantic non-targeted biopsies were taken every 10 cm. Pancolonic indigo carmine (0.1%) was used during the second colonoscopic examination, and any additional visible abnormalities were biopsied.
RESULTS: Median extubation times for the first and second colonoscopies were 11 and 10 minutes, respectively. The non-targeted biopsy protocol detected no dysplasia in 2904 biopsies. Forty three mucosal abnormalities (20 patients) were detected during the pre-dye spray colonoscopy of which two (two patients) were dysplastic: both were considered to be dysplasia associated lesions/masses. A total of 114 additional abnormalities (55 patients) were detected following dye spraying, of which seven (five patients) were dysplastic: all were considered to be adenomas. There was a strong trend towards statistically increased dysplasia detection following dye spraying (p = 0.06, paired exact test). The targeted biopsy protocol detected dysplasia in significantly more patients than the non-targeted protocol (p = 0.02, paired exact test).
CONCLUSIONS: No dysplasia was detected in 2904 non-targeted biopsies. In comparison, a targeted biopsy protocol with pancolonic chromoendoscopy required fewer biopsies (157) yet detected nine dysplastic lesions, seven of which were only visible after indigo carmine application. Careful mucosal examination aided by pancolonic chromoendoscopy and targeted biopsies of suspicious lesions may be a more effective surveillance methodology than taking multiple non-targeted biopsies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14724160      PMCID: PMC1774934          DOI: 10.1136/gut.2003.016386

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance.

Authors:  J A Eaden; B A Ward; J F Mayberry
Journal:  Gastrointest Endosc       Date:  2000-02       Impact factor: 9.427

2.  Precancer and carcinoma in chronic ulcerative colitis. A histopathological and clinical investigation.

Authors:  L Hultén; J Kewenter; C Ahrén
Journal:  Scand J Gastroenterol       Date:  1972       Impact factor: 2.423

3.  Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia.

Authors:  A J Woolrich; M D DaSilva; B I Korelitz
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

4.  Laser-induced fluorescence spectroscopy of human colonic mucosa. Detection of adenomatous transformation.

Authors:  C R Kapadia; F W Cutruzzola; K M O'Brien; M L Stetz; R Enriquez; L I Deckelbaum
Journal:  Gastroenterology       Date:  1990-07       Impact factor: 22.682

5.  Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy.

Authors:  M O Blackstone; R H Riddell; B H Rogers; B Levin
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

6.  Ulcerative colitis and colonic cancer. Problems in assessing the diagnostic usefulness of mucosal dysplasia.

Authors:  D F Ransohoff; R H Riddell; B Levin
Journal:  Dis Colon Rectum       Date:  1985-06       Impact factor: 4.585

7.  Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.

Authors:  W R Connell; J E Lennard-Jones; C B Williams; I C Talbot; A B Price; K H Wilkinson
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

8.  Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance.

Authors:  B A Taylor; J H Pemberton; H A Carpenter; K E Levin; K W Schroeder; D R Welling; M P Spencer; A R Zinsmeister
Journal:  Dis Colon Rectum       Date:  1992-10       Impact factor: 4.585

9.  DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis.

Authors:  C E Rubin; R C Haggitt; G C Burmer; T A Brentnall; A C Stevens; D S Levine; P J Dean; M Kimmey; D R Perera; P S Rabinovitch
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

Review 10.  Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?

Authors:  C N Bernstein; F Shanahan; W M Weinstein
Journal:  Lancet       Date:  1994-01-08       Impact factor: 79.321

View more
  99 in total

1.  Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols.

Authors:  Ute Günther; Dajana Kusch; Frank Heller; Nataly Bürgel; Silke Leonhardt; Severin Daum; Britta Siegmund; Christoph Loddenkemper; Maria Grünbaum; Heinz-Johannes Buhr; Jörg-Dieter Schulzke; Martin Zeitz; Christian Bojarski
Journal:  Int J Colorectal Dis       Date:  2011-01-29       Impact factor: 2.571

2.  Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight.

Authors:  R Kiesslich; M F Neurath
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

3.  Random versus targeted biopsies for colorectal cancer surveillance in inflammatory bowel disease.

Authors:  Tasneem Ahmed; Jennifer Monti; Bret Lashner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

4.  Should chromoendoscopy be the standard of care in ulcerative colitis dysplasia surveillance?

Authors:  Thomas A Ullman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-10

5.  Target biopsy or step biopsy? Optimal surveillance for ulcerative colitis: a Japanese nationwide randomized controlled trial.

Authors:  Toshiaki Watanabe; Yoichi Ajioka; Takayuki Matsumoto; Naoki Tomotsugu; Toru Takebayashi; Eisuke Inoue; Bunei Iizuka; Masahiro Igarashi; Yasushi Iwao; Kazuo Ohtsuka; Shin-ei Kudo; Kiyonori Kobayashi; Miwa Sada; Takayuki Matsumoto; Ichiro Hirata; Kazunari Murakami; Masakazu Nagahori; Kenji Watanabe; Nobuyuki Hida; Fumiaki Ueno; Shinji Tanaka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2010-11-02       Impact factor: 7.527

6.  [Endomicroscopy--technology with future].

Authors:  R Kiesslich; M Götz; M F Neurath; P R Galle
Journal:  Internist (Berl)       Date:  2006-01       Impact factor: 0.743

7.  Is chromoendoscopy the new standard for cancer surveillance in patients with ulcerative colitis?

Authors:  Markus F Neurath; Ralf Kiesslich
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-01-27

Review 8.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11

Review 9.  Indications, stains and techniques in chromoendoscopy.

Authors:  P J Trivedi; B Braden
Journal:  QJM       Date:  2012-10-24

Review 10.  Endoscopic and pathological aspects of colitis-associated dysplasia.

Authors:  Fiona D M van Schaik; G Johan A Offerhaus; Marguerite E I Schipper; Peter D Siersema; Frank P Vleggaar; Bas Oldenburg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-22       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.